MedTrace Logo

OCT-angiography in Diabetic Patients

NCT02870803 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-04-25

No results posted yet for this study

Summary

Around the world there is an increasing incidence of diabetes mellitus, with millions of people affected. In this population, diabetic macular edema (DME) is the most common cause of visual impairment. While the visual impairment caused by EMD is variable, its early treatment can improve visual acuity and quality of life. The objective of this project is to use the new OCT-angiography technology, which evaluates macular capillary network without the need of intravenous injection of contrast, to assess macular microcirculatory network in its response to intravitreal pharmacological treatment of EMD. The resulting qualitative evaluation can be helpful in understanding the pathophysiology of visual loss associated with DME and in determining prognosis.

Conditions

Sponsors & Collaborators

  • Retina Clinic, Sao Paulo, Brazil

    lead OTHER

Principal Investigators

  • André Maia, M.D. · Retina Clinic CEO

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-11-30
Completion
2018-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02870803 on ClinicalTrials.gov